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When Is It Time to Get Married? orWhen
Should the Assay User and the Assay
Developer Collaborate?
byShanna H. Swan* and Bill L. Lasley*
HormOn asYs arebeingdeoped nthe rty todeect ecm rmkersinnOnClIniCaI populations.
Epidem isinc ly uwngtheseass to mprvethepionwihwhichdise pses andexpoes can
bdefined. Thisgro nboyfmre Iogyr esahlghdegreeofo betwh themaey developer
andtheas user. Mkdraw oure nce inasense hormne forthedetectionofearl pny via
urinaryhumanchorionicgonadotropintoflstratethesepoints Weconcudethatthiscfborativeefort,inaddition
tomakingthiSstudypossible, hasprovided rewards.
"But those epidemiologists don't understand the physiologic basis ofthese
studies," theendocrinologisttellshiscolleagues. "Thoseendocrinologists are
lost indetail; they study a fewpeopleendlessly," theepidemiologist reports.
Given the wide gulfbetween theseviews, can a "marriage"
betweenepidemiologyandendocrinologysucceed?Iftheanswer
isintheaffirmative, underwhatconditionsissuchaunionlikely
tobesuccessful?Whatis thelikelyproductofsuchaunion?We
attempt to answer these questions using our experience in a
collaborativeeffortbetweenendocrinologyandepidemiologyin
the study of early pregnancy loss. In particular, we describe
conditions under which an assay is likely to be useful to the
epidemiologist as abiomarker inlargepopulations.
Background
Hormone Assays
Priorto thediscovery andapplicationofradioimmunoassays
in theearly andmid-1970s, analytic techniques such as colori-
metry, gas-liquidchromataphy, competitiveproteinbinding,
anddoubleisotopedilutionmethods wereemployedto measure
hormone concentrations. These tests wereeithertoolaborious
or insensitive to be practical for routine monitoring. These
methods were, however, quiteuseful formeasuring changes in
urinary hormone excretion because of the large quantities of
urinethatcouldbeeasilycollectedandthehigherconcentration
ofhormones in urinecompared toplasma or serum.
Withtheadventoftheradioimmunoassay (forwhichBerson
andYallow wereawarded theNobelprize), assaysbecamemore
sensitive, and it was considered more appropriate to measure
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theactivecompoundincirculationratherthanitsmetabolitein
theexcreta. This,then,becametheacceptedstandardinthefield
andreplacedtheuseofurinary assays forresearch purposes.
Subsequendy (1978-1980), urinaryandfecal steroidhormone
metabolitemonitoring methods weredeveloped inthezoo set-
tingtoobtainbiologicalsampleswithoutcaptureandrestraint.
These second-generationassaystookadvantage oftheimprov-
ed technology that had been developed for serum and plasma
assays andapplied ittourineand feces (1). Morerecently, the
recognitionoftheadvantages ofcollectingandanalyzingurine
inhumanpopulationshasrenewedinterestinthisapproach(2).
Unlikebloodsampling,urinesampling, whichisnonintrusive,
can be accomplished in large populations with a high level of
compliance, samples can be collected over a prolonged time
period, andcollectionrequiresnospecialskillsorinstruments.
Untilrecently, theassaysemployedtomeasurehornoneshave
beenradioimmuno-orradiometricassaysappliedtosmallclinic
populations (3). Continueddevelopments inthisfieldhaveled
to an array of assays that eliminate the need for radioactive
materials, and in some case, obviate the need foralaboratory
(4,5). The combined result ofthe concentrating effect ofthe
kidney, the lack of binding proteins in urine, and the water-
soluble nature ofthe hormone metabolites allows virtually all
assay formats to be applied to unprocessed urine. Although
dipstickkitsareavailableforonlyafewhormones, morewillbe
availableshortly(6). Theendresultwillbeaseriesofeasy-to-
use, sensitive, andspecificassaysforuseinlargeepidemiologic
populations.
Epidemiology
Untilrecendy,whensensitiveurinaryassaysbecameavailable,
epidemiologists interestedinsubfecundity andearlypregnancy
loss werelimitedto suchindirectmeasuresasthenumberand
timing of births or the study of spontaneous abortion usingSWANANDLASLEY
timing of births or the study of spontaneous abortion using
clinically observable end points. However, it has long been
suspected that clinically recognized fetal loss represents only
a fraction of total postconception loss, although previous
estimates of the magnitude of this loss have varied widely
(7,8). Moreover, pregnancy loss is a relatively crude indicator
of reproductive dysfunction; hormone levels, length of the
luteal phase, and ovulation, ifmeasurable, might provide more
direct indicators of female reproductive health.
Even the study of clinically recognized spontaneous abor-
tion is difficult. The earlier in gestation that a pregnancy is
recognized by a woman or her health-care provider, the
greater the probability that a spontaneous abortion will be
reported. This is further complicated by the fact that women
at high risk of loss, whether on the basis of past history, age,
or symptoms in a current pregnancy, are more likely to seek
early prenatal care. Therefore, losses in these high-risk
groups are more likely to be documented. This form of
selection bias is likely to be present in all epidemiological
studies of clinically recognized pregnancy, regardless of
design.
In addition, there are problems specific to the particular
design used. Case-control studies must rely on self-reported
pregnancy loss, which may be over- or underreported.
Medical record review will minimize overreporting, but
underreporting, particularly if differential, may remain a pro-
blem. Furthermore, retrospective recall of exposures that are
likely to be poorly recalled may be problematic. On the
other hand, cohort studies of recognized pregnancies may
underestimate spontaneous abortion rates, since many losses
occur either before the subject is identified as a cohort
member or between the time the subject is identified and the
interview. For example, spontaneous abortion rates in the
literature, based on retrospectively recalled, self-reported
loss, are 10 to 15% (9,10). In contrast, a recent case-cohort
study found a crude spontaneous abortion rate of only 7.5%
(11).
There is a way out of this dilemma: conduct careful sur-
veillance on a group of women "at risk of pregnancy" and
follow them uniformly to determine pregnancy outcome.
There are several levels at which this surveillance can be car-
ried out. The least sensitive of these methods would be to
distribute home pregnancy kits to study subjects after they
miss a menstrual period. A somewhat more sensitive method
has been used in which women tested their own urine using
home kits for a fraction ofeach month, whether or not a men-
strual period had been missed (12). Alternatively, one can
detect pregnancies as early as the seventh postconception day
by conducting ongoing surveillance through sensitive urinary
hormone assays carried out by an endocrine laboratory. This
is the option we have chosen.
This choice was made possible by the recent development
of a relatively inexpensive urinary hormone assay (13). Not
only does this assay satisfy the usual laboratory requisites of
sensitivity and specificity, but it also satisfies the conditions
discussed below for successful cooperation between the
laboratory scientist and the epidemiologist. This assay has
successfully been used in one epidemiologic study (14) and
is currently employed in several ongoing studies.
Prerequisites foran Effective
Collaboration between Laboratory
Scientist and Epidemiologist
Conditions on theAssay
Itisofprimary importancethattheassay detectanendpoint
thatisbothofepidemiologicandclinicalinterest. Thatis, theend
point must be sufficiently common to warrant epidemiologic
study. A rare genetic defect, which might have clinical sig-
nificance, wouldnotbeofgreatepidemiological interest. Con-
versely, theepidemiologistisunlikelytofindanassaydeveloped
unless it is clinically useful.
Needs forsensitivity and specificity differ somewhat forthe
laboratory scientistandtheepidemiologist. Theepidemiologist
wantsanassaywithlow false-positiverate(high specificity), for
example, toavoidfalselytellingwomenthatthey arepregnant.
Ontheotherhand, theepidemiologist, knowingthatitis never
possibletodetectallpregnancies, maybelessconcernedabout
sensitivitythanthelaboratory scientist. However, itisimportant
toboth members ofthe teamthatthe assay behighly reliable.
Theassayshouldbeeasilyusableinmultiplelaboratories, and
allreagentsshouldbeavailableforalongperiodoftime. Forex-
ample, whentherabbitthatproducedtheantibodyusedbyCan-
field(13)died, theresultingshortageofantibodydelayedtheuse
ofradioimmunoassays forstudiesofearlypregnancy loss. For-
tunately, amonoclonal antibodythathasthedesiredproperties
is now available.
Tobeusefulepidemiologically, anassay shouldusespecimens
orsamplesthatareeasilyobtainable, suchasurine. Thecollec-
tionmethodshouldrequireaminimumofskillandequipment.
Forexample, assaysonbonemarroworfattissueareclearlynot
useful inlargepopulations. Inaddition, theassay shouldnotre-
quire large volumes of specimens. For example, the original
humanchorionicgonadotropin (hCG) assays required40times
theamountofurinenowused. Currentassays requireless than
5 mL of urine, so it is now practical to ask women to store
samples in theirhome freezers.
Thecollectionprocedureshouldbesuchthatitcanbeimposed
onsubjectsforalongtimeperiod. Basedononlyafewsamples,
it is not possible to establish "baseline" measurements, or to
assess intrasubject variability. When infrequent events like
pregnancy are under study, even more measurements are re-
quired. Subjects intheWilcoxandCanfield study (13,14) were
requiredtocollecturinefor6monthsoruntilpregnant. Asimilar
protocolisbeingfollowedincurrentstudies. Inaddition, itisim-
portantthatthetimingofspecimencollectionandstoragenotbe
too critical. Fortunately, urine collection for hCG and steroid
assayscanbedoneathome, andtheseassaysarenotsensitiveto
temperaturechangesorfreeze-thawcycles. Infact, futureurine
assays may useasampleadsorbed ontofilterpaper, whichwill
notrequirecold storageatall.
Finally, assay costs shouldbelowenough tomakestudies in
largepopulations feasible.
Conditions onResearchers
Thedistributionoftheendpointsassayedinlargepopulations
must be ofinterest to the laboratory scientist as well as to the
epidemiologist. The study of large populations rather than
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individuals requires thinking in probabilistic and statistical
terms. This frame of reference may be unfamiliar to the
laboratory-based scientist. Conversely, theepidemiologistmust
bewillingtothinkabouttheclinical implicationsoflaboratory
results, whichmaybeequallyunfamiliar. Thus, bothmembers
oftheteammustbewillingtoinvestappreciableamountsoftime
learning about the field ofmutual collaboration, so that inter-
pretation ofassay findings will be biologically and epidemio-
logically meaningful.
Theprimary interestofthe laboratory scientistmay well be
assaydevelopment. However, forthiscollaboration towork, a
laboratorymustbesetuptoperformlargenumbersofrepeated
measurements. Thisinvolvesthedevelopmentoftechniquesfor
themeticulouslabeling, handling, andstorageoflargevolumes
ofsamples. Forexample, acurrentstudybeingconductedbythe
CaliforniaDepartmentofHealthServices incollaborationwith
theEndocrineLaboratoryattheUniversityofCaliforniaatDavis
(theWomen'sReproductiveHealthStudy)willrequirehandling
close to 100,000urinesamples.
Thistaskisbeingfacilitatedbythedevelopmentofcomputer-
izeddatacollectionmethodsthatcanhandletheaccumulationof
large numbers of laboratory samples. For example, for our
studies, stafffromtheepidemiology andendocrinologygroups
have worked together to develop a bar-code-readable labeling
andtrackingsystemtofacilitatestorageandretrievalofthelarge
volume of samples anticipated. This is a new area for both
membersoftheteam;epidemiologistsareusedtohanlinglarge
volumes ofquestionnaires butnotusually laboratory samples.
Theepidemiologistmustbewillingtoadaptfieldmethodsand
evenquestionnairestothedemandsoftheassay. Forexample, for
theWmen'sReproductiveHealthStudy,theendocrinologisthas
specifiedvolumeandfrequencyofsamplecollection, amountof
samplecollected, andtheprotocol for storageandtransportof
samples.
Othersinthefield(bothassaydevelopersandassayusers)must
also be willing to collaborate in order to standardize both lab-
oratory andfield methods sothatresults frommultiple studies
arecomparable.
Conclusion
Undertheseconditions, theunionofthelaboratoryassaywith
the epidemiological study can be very fruitful, with benefits,
both expected and unexpected, to the epidemiologist and the
assaydeveloper.
Epidemiologists turned to studiesofearly pregnancy loss in
order toa) detectearly losses, whichmay beetiologically dif-
ferent from later losses; b) increase study power (in any fixed
samplesize) byincreasingthenumberofmeasurablepregnan-
cylosses; c) minimizemisclassificationoftheseoutcomes; and
d)decreaseselectionbias. Alloftheseaimsarelikelytobemet
inourjointeffort. Itislikelythatthemeasurablerateofpregnan-
cylosswillbeaboutthreetimeshigherinthesestudiesthanthat
observable without the use ofhormone assays (14). Clearly,
pregnancylossesdefinedbyassayofbiologicalsampleswillhave
much greater precision than if studied only through medical
recordsorself-report. Studiesconductedusingchemicalassay
ofbiological samples should not be subject to selection bias,
sincetheoutcomes canbedeterminedblindlyboth forthesub-
jectandtheresearcher.
Inaddition, wehopetolearnaboutnewhealthendpointsthat
might not be studied otherwise. Since this collaboration has
begun, ithasbecomeclearthatreproductiveparameters, such
aslutealphaseabnormalities, anovulation, anddecreasedhor-
monelevels, canbestudiedinadditiontoearlypregnancyloss.
Theseadditionalparametersmayturnouttobeevenmoreuseful
and could not have been studied in large populations in the
absenceofurinary steroidassays.
Theassaydevelopertunedtoepidemiologyinordertounder-
standtheprofile(mean, range, variability)oftheassayingeneral
populations. Thisinformationisnecessaryinorderthatclinical
datainselectedpopulationsbeproperlyinterpreted. Ourrecent
collaborativeefforts shouldprovidethis information.
Additionally, throughcollaboration withtheepidemiologist,
theassaydeveloperlearnstothinkaboutthepopulation rather
thanjustthe individual. In fact, the "unit ofobservation" has
changed for the endocrinologists working on the Women's
ReproductiveHealthStudy. Whileindividualsampleswerethe
unitofobservationinthepast, theendocrinologistsnowviewthe
entiremenstual cycleastheunitofobservation.
Forresearchersfrombothdisciplines, dataresultngfromsuch
acollaborativestudywillbemoreeasilyinterpretable; biological
mechanisms involved in any observed association should be
clearertotheepidemiologist, andclinicalabnormalities should
bemoreunderstandabletotheendocrinologistinthecontextof
backgroundrates.
TheprocessofcollaborationwhichourworkontheWomen's
ReproductiveHealthStudyhasrequired, evenpriortocomple-
tionofdatacollection, hasalteredour hinindnginprofoundways.
Forexample,priortothiscollaboration, bothdisciplinesviewed
conceptionasan"allornothing"phenomenon. Itwasastanding
jokethatyoucouldnotbe "alittlebitpregnant:" Withincreased
understandingbytheepidemiologistofthesubtletiesinvolvedin
classifyingcyclesas "conception" or "nonconception" andan
awareness by the endocrinologist ofthe power ofprobability
dteorytodealwithsuchuncertainty, wenowspeakaboutthepro-
bability of conception in a given cycle. In fact, we are now
allowingforatfirdalternativeinourmodel,thatofbeing "alittle
bitpregnant."
The principles discussed could equally well apply to assays
detectingothermarkersofdisease(e.g., DNAdamageorsperm
abnormalities) or markers ofexposure (e.g., saliva assays for
cotinine,nicotine,andcaffeine). Thiskindofcollaborativeeffort
islikelytobeofparticularbenefittoenvironmentalepidemiol-
ogy. In the past, environmental studies have often been weak
becauseofpoor assessment ofexposure and outcome, both of
whichareoftenself-reported. Theuseofbiomarkersprovidea
meansofsharpeningthetoolsavailabletoepidemiologists. Atthe
same time, it provides a population-based context in which
researchersinthelaboratorycaninterprettheirassays. Welook
forwardtocontinuedfruitfulcollaborationofbenefittoboththe
assaydeveloperand the assay user.
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